
|Articles|June 5, 2015
Nivolumab Shows Promise Versus Docetaxel for NSCLC in Checkmate 057 Trial
Author(s)David Carbone, MD, PhD
David Carbone, MD, PhD, professor, internal medicine, College of Medicine Director, James Thoracic Center, James Cancer Hospital and Solove Research Institute at Ohio State University Medical Centerdiscusses the Checkmate 057 trial, which evaluates Opdivo (nivolumab) versus docetaxel in previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
5

























